论文部分内容阅读
目的 探讨新辅助化疗对手术安全性的影响。方法 1995年 1月～ 1999年 12月 ,对 5 0例 A NSCL C患者行辅助化疗 ,选择同期行单纯手术 A NSCL C患者作为对照 ,所有病例均行肺叶或全肺切除术加纵隔淋巴结清扫术 ,以肺感染、需行药物治疗心律失常、支气管残端瘘、气管切开发生率、肺不张发生率作为手术合并症的观察指标 ,比较两组病例手术期合并症和死亡。结果 新辅助化疗组术后心律失常发生率明显多于对照组 (2 4% :6 % ,P<0 .0 5 ) ,而肺感染、支气管残端瘘、气管切开、肺不张发生率两组无差别 ,新辅助化疗组中有 2例术后死亡。结论 新辅助化学在一定程度增加手术的合并症和死亡 ,应给予重视 ,并采取积极预防措施
Objective To investigate the effect of neoadjuvant chemotherapy on surgical safety. Methods From January 1995 to December 1999, 50 patients with A NSCL C were treated with adjuvant chemotherapy. The patients who underwent surgery alone with NSCL C were selected as controls. All patients underwent lung or pneumonectomy plus mediastinal lymph node dissection. The complications of complications and deaths were compared between the two groups of patients with lung infections, medications for arrhythmia, bronchial stump fistula, tracheotomy and atelectasis rates as observation indicators of surgical complications. Results The incidence of postoperative arrhythmia in the neoadjuvant chemotherapy group was significantly higher than that in the control group (2 4% : 6%, P < 0.05). Lung infection, bronchial stump fistula, tracheotomy, and incidence of atelectasis There was no difference between the two groups. Two patients in the neoadjuvant chemotherapy group died after the operation. Conclusion The neoadjuvant chemistry may increase the complications and death of the operation to a certain extent and should be given attention and take active preventive measures.